The text starts here.

News Release

FOR IMMEDIATE RELEASE
December 1, 1998

Eisai's German Subsidiary Begins Sales of PARIET, a Proton Pump Inhibitor

Tokyo (December 1, 1998) - Eisai Co., Ltd. of Tokyo (President and CEO:Haruo Naito) today announced that Eisai GmbH, an Eisai marketing subsidiary, has started sales of the proton pump inhibitor, PARIET (rabeprazole sodium, research code name: E3810) a new treatment for the healing for gastroesophageal reflux disease (GERD), duodenal and gastric ulcers.


Rabeprazole sodium is classified as a proton pump inhibitor and was synthesized by Eisai in Japan. The compound has been developed by Eisai in Japan, Europe, and the US. Rabeprazole sodium demonstrates strong proton pump inhibition at the final stage of acid secretion by blocking the function of the enzyme responsible for stomach acid production.


Eisai GmbH received marketing authorization from the German Federal Institute on Drugs and Medical Devices (BfArM) on November 11. Sales began in Japan in December 1997 and in the U.K. in September 1998 under the tradename of PARIET. A New Drug Application for marketing clearance was filed with the U.S. Food and Drug Administration in March 1998.


In Europe a copromotion alliance with Janssen Pharmaceutica (Headquarters: Beerse, Belgium) exists for rabeprazole sodium sales in the U.K., Germany, and France. Sales in the other European countries will be through Janssen-Cilag, except for Belgium, the Netherlands, and Luxemburg where Janssen-Cilag does not have the license.


Janssen Pharmaceutica is a wholly owned subsidiary of Johnson & Johnson, the world's most comprehensive manufacturer of healthcare products and related services. Janssen is a leader in the research and development of therapies for gastrointestinal disorders with affiliates in 32 countries.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of worldwide health care systems. The company reported sales of about $2.3 billion in 1997 with approximately 15 percent of sales spent for research and development.


### ### ###


PARIET is a trademark of Eisai Co., Ltd.